Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olivier Trédan

Showing results (1-10 of 97) with videos related to

Pageof 10
Sort By:
Targeted Oncology|November 14, 2013
Trends in cancer-targeted antibody-drug conjugatesFrançois-Clément Bidard, Olivier Trédan
Bulletin Du Cancer|June 11, 2008
[Can tumor hypoxia be turned into a chemotherapeutic advantage?]Olivier Trédan, Rama Grantab, Charles Dumontet
Cancer Chemotherapy and Pharmacology|May 18, 2013
Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissuesKrupa J Patel, Olivier Trédan, Ian F Tannock
Bulletin Du Cancer|December 19, 2012
[Antibody-drug conjugates in oncology: from the concept to trastuzumab emtansine (T-DM1)]Anthony Gonçalves, Olivier Trédan, Christian Villanueva, et al.
Bulletin Du Cancer|January 30, 2023
[Use of genome-wide testing in oncology: French expert opinion based on the Delphi methodology]Olivier Trédan, Caroline Robert, Antoine Italiano, et al.
The Lancet. Oncology|December 18, 2010
The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancerLars Petter Jordheim, Pascal Sève, Olivier Trédan, et al.
International Journal of Molecular Sciences|December 24, 2021
Targeting AKT in ER-Positive HER2-Negative Metastatic Breast Cancer: From Molecular Promises to Real Life Pitfalls?Benoîte Mery, Coralie Poulard, Muriel Le Romancer, et al.
Journal of the National Cancer Institute|September 27, 2007
Drug resistance and the solid tumor microenvironmentOlivier Trédan, Carlos M Galmarini, Krupa Patel, et al.
Mutagenesis|February 18, 2015
Therogenetics: transferring GWAS technology to the clinicDavid G Cox, Pierre-Etienne Heudel, Olivier Trédan, et al.
Cancer Research|January 30, 2009
The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantroneOlivier Trédan, Alaina B Garbens, Alshad S Lalani, et al.
Pageof 10

Showing results (1-10 of 97) with videos related to

Sort By:
Pageof 10
Targeted Oncology|November 14, 2013
Trends in cancer-targeted antibody-drug conjugatesFrançois-Clément Bidard, Olivier Trédan
Bulletin Du Cancer|June 11, 2008
[Can tumor hypoxia be turned into a chemotherapeutic advantage?]Olivier Trédan, Rama Grantab, Charles Dumontet
Cancer Chemotherapy and Pharmacology|May 18, 2013
Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissuesKrupa J Patel, Olivier Trédan, Ian F Tannock
Bulletin Du Cancer|December 19, 2012
[Antibody-drug conjugates in oncology: from the concept to trastuzumab emtansine (T-DM1)]Anthony Gonçalves, Olivier Trédan, Christian Villanueva, et al.
Bulletin Du Cancer|January 30, 2023
[Use of genome-wide testing in oncology: French expert opinion based on the Delphi methodology]Olivier Trédan, Caroline Robert, Antoine Italiano, et al.
The Lancet. Oncology|December 18, 2010
The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancerLars Petter Jordheim, Pascal Sève, Olivier Trédan, et al.
International Journal of Molecular Sciences|December 24, 2021
Targeting AKT in ER-Positive HER2-Negative Metastatic Breast Cancer: From Molecular Promises to Real Life Pitfalls?Benoîte Mery, Coralie Poulard, Muriel Le Romancer, et al.
Journal of the National Cancer Institute|September 27, 2007
Drug resistance and the solid tumor microenvironmentOlivier Trédan, Carlos M Galmarini, Krupa Patel, et al.
Mutagenesis|February 18, 2015
Therogenetics: transferring GWAS technology to the clinicDavid G Cox, Pierre-Etienne Heudel, Olivier Trédan, et al.
Cancer Research|January 30, 2009
The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantroneOlivier Trédan, Alaina B Garbens, Alshad S Lalani, et al.
Pageof 10